Tuberculosis is a major health problem afflicting the world, especially the third world countries.
INTRODUCTION
Tuberculosis (TB) continues to haunt mankind & remains a world wide health problem even today, despite isolation of its causative agent, advent of BCG Vaccine & availability of effective chemotherapeutic agents. According to WHO, one third of the world population is infected with Mycobacterium Tuberculosis. The disease is taking heavy toll on the third world countries of Asia & Africa. HIV epidemic & emergence of resistant forms of TB especially MDR-TB together have added a new dimension to the problem. It is well known that people living with HIV/AIDS are very susceptible to contracting TB as compared to general population. The incidence of MDR-TB is also higher in these patients. In the last two decades there have been a number of outbreaks of M D R-TB in United States 
Second line drugs
The second line drugs have lower efficacy and are associated with more adverse effects in comparison to the first line agents & are therefore used in special circumstances such as for treatment of MDR-TB. This group includes Aminoglycosides such as Kanamycin, Amikacin and Capreomycin, Flouroquinolones such as Ofloxacin, Moxifloxacin, Levofloxacin, oral bacterostatic agents such as Ethionamide , Prothionamide, Cycloserine, Terizidone, p-aminosalicylic acid (PAS) and 'Group Five' drugs which includes Clofazimine, Linezolid, Amoxicillin/Clavulanate, Thioacetazone, Clarithromycin, and Imipenem.
Macrolide antibiotics
Drugs such as Azithromycin , Clarithromycin are used for the treatment of infections caused by atypical Mycobacteria.
Multi-drug resistant tuberculosis (Mdr-tb)
It is defined as the disease caused by M.Tuberculosis that is resistant to at least Isoniazid (INH) & Rifampicin, with or without resistance to other anti-TB drugs 6 . The drug treatment of MDR-TB is difficult as the options are limited owing to the resistance to INH & Rifampicin, two of the most potent anti-TB drugs.
Magnitude of the Problem
As 8 . It is also established that the drug / multi-drug resistant strains of M. Tuberculosis can cause very severe disease. Further, the treatment of MDR-TB is not as effective as the treatment of drug susceptible TB. In last few years there have been reports of what has been described as 'Extensively Drug Resistant TB (XDR-TB)'. XDR-TB is a form of MDR-TB where the patients have resistance to Second Line anti-TB drugs as well. XDR-TB has drastically reduced the treatment options for the patients concerned.
Diagnosis / Detection of MDR-TB Drug / multi-drug resistant TB should be suspected in patients if
Patient has taken treatment for Tuberculosis in the past. INH resistance prevalence in community is more than 4 percent. There is likelihood of patient being exposed to MDR-TB. There is poor response to the drug treatment as indicated by prolonged fever or cough, sputum conversion failure despite four months of standard short course chemotherapy 9 .
Mycobacteria grow slowly and hence drug susceptibility tests take about 10-12 weeks. Thus rapid testing methods are necessary to detect drug resistance early & institute appropriate drug treatment. Slide culture sensitivity methods (detect drug resistance in about a week 10 , phage based method using the 'Luciferase incorporated Phage [11] [12] [13] , BACTEC method (Radiometric 16 are some of the rapid testing methods to detect drug resistance. Currently such rapid testing methods are beyond reach of most laboratories due to cost factor.
Treatment of Multi-drug Resistant TB (MDR-TB)
In general, the treatment of Multi-Drug
Resistant TB is less effective. The cost of the treatment as well as the incidence of adverse effects is higher in comparison to the treatment of drug susceptible TB. The WHO has issued important guidelines for the management of drug / Multi-Drug Resistant TB. 
WHO guidelines for the drug treatment of MDR-TB While designing the regimen for MDR-TB patients

WHO has recommended anti TB regimens for treatment of MDR-TB according to the availability / unavailability of drug susceptibility tests results
Regimen for MDR-TB patients when drugs susceptibility tests are unavailable: (Table III) Pyrazinamide and at least 3 drugs, which the patient has never received before, are chosen for initial phase. If drug susceptibility tests are not available even after sputum conversion , two best tolerated & more active drugs should be continued for 18 months.
There is lack of reliable information on susceptibility of M.Tuberculosis to Pyrazinamide. In case there is proven resistance to Pyrazinamide & if it correlates with clinical data Pyrazinamide may be replaced with Cycloserine or PAS. Usually resistance to Pyrazinamide is unlikely even if it has been used before in the patient. Regarding Rifampicin, there is lack of information on the effective regimens for patients in whom monoresistance to Rifampicin is demonstrated. If the bacilli are resistant to Isoniazid & Rifampicin, a 5-drug regimen should be used for initial phase.
Patients of MDR-TB require second line drugs, which are less effective & have more adverse effects as compared to first line drugs. So the patient must be encouraged to tolerate the adverse effects. It should be imbibed upon the patient that compliance with the prescribed regimen alone can prevent the death. Psychological support to the patient is also of paramount importance.
Extremely Drug Resistant TB (XDR-TB) WHO Consultation on the diagnostic definition and treatment options (21-22 March 2012) Main conclusionś
Although there is increased incidence of Tuberculosis (TB) patients with severe patterns of drug resistance which is posing a formidable challenge to the clinicians, a new definition of resistance beyond Extensively Drug-Resistant TB (XDR-TB ) is not recommended, owing to the technical difficulties with drug susceptibility testing (DST) of many anti-TB drugs, insufficient evidence to link such DST results to treatment outcomes of patients, and the lack of standardized DST methods for several anti-TB drugs. Rapid drug susceptibility testing (DST) of Isoniazid and Rifampicin or of Rifampicin alone is recommended over conventional testing or no testing at the time of diagnosis of TB, subject to available resources. The use of sputum smear microscopy and culture rather than sputum smear microscopy alone is recommended for the monitoring of patients with MDRTB during treatment.
In the treatment of patients with MDR-TB, a fluoroquinolone should be used.
In the treatment of patients with MDR-TB, a later-generation fluoroquinolone rather than an earlier-generation fluoroquinolone should be used. In the treatment of patients with MDR-TB, Ethionamide or Prothionamide should be used.
In the treatment of patients with MDR-TB, four second-line anti TB drugs likely to be effective (including a parenteral agent), as well as pyrazinamide, should be included in the intensive phase.
In the treatment of patients with MDR-TB, regimens should include at least Pyrazinamide, a fluoroquinolone, a parenteral agent, Ethionamide (or Prothionamide), and either Cycloserine or PAS (p-aminosalicylic acid) if Cycloserine cannot be used.
In the treatment of patients with MDR-TB, an intensive phase of at least 8 months' duration is recommended.
In the treatment of patients with MDR-TB, a total treatment duration of at least 20 months is recommended in patients without any previous MDR-TB treatment. Antiretroviral therapy is recommended for all patients with HIV and drug-resistant TB requiring secondline anti-tuberculosis drugs, irrespective of CD4 cell-count, as early as possible (within the first 8 weeks) following initiation of antituberculosis treatment.
Prospectus
Newer Rifamycins such as Rifabutin, Rifapentin, Rifalazil & newer quinolones like Levofloxacin,Moxifloxacin appear promising to deal with MDR-TB. There are reports suggesting the usefulness of β-Lactam antibiotics such as Imipenem, Amoxicillin -Clavulanic acid in treatment of MDR-TB. Linezolid is an oxazolidinone derivative, which acts by inhibiting early steps of protein synthesis in the Mycobacteria & is found to be useful in MDR-TB. Several other drugs such as interferon-γ, recombinant human interleukin 2 have been reportedly useful in MDR-TB. Currently these drugs are under clinical trials. As the treatment of MDR-TB has been found to be less effective, resectional surgery has been advocated in selected patients of MDR-TB who have good respiratory reserve & in whom drug treatment alone is not working.
